Rheumatoid Arthritis pain
Imagine knowing if a treatment will work before you take it. Roughly 1 in 3 people living with rheumatoid arthritis (RA) who are prescribed a biologic (anti-TNF) therapy such as Humira®, Enbrel®, Remicade®, Cimzia®, Inflectra®, Simponi®, or Simponi Aria® will adequately respond to treatment. Currently, there is no tool to predict which person will respond to these drugs. Scipher Medicine aspires to change this with PrismRATM, a new test that could improve how RA is treated.
PrismRATM is an experimental blood test that may predict non-response to biologic therapies in people living with RA. This could help patients get faster access to the right therapies, saving ‘non-responders’ time and potential side-effects caused while on ineffective drugs.
All study-related care will be at no cost to you and you can continue seeing your family doctor during the study. Doctor referrals aren't required to participate. To learn more about this study: https://www.sciphermedicine.com/trials/
Please contact one of our study coordinators at (316) 838-7700 or click on the button below to set up a phone screening appointment